Results 351 to 360 of about 10,143,464 (406)
Some of the next articles are maybe not open access.
Albuminuria and cardiovascular risk
Hipertensión y Riesgo Vascular, 2023Cardiovascular risk (CVR) estimation is a fundamental tool for guiding therapy. Albuminuria indicates target organ damage in an accessible, economic and non-invasive manner. Improves high-risk patient identification, especially in chronic kidney disease (CKD) and diabetes mellitus (DM). In addition, anti-albuminuric treatments may improve CVR.
D H, Rigo, P M, Jiménez, M, Orias
openaire +2 more sources
Predicting Cardiovascular Risk Factors from Retinal Fundus Photographs using Deep Learning
arXiv.org, 2017Traditionally, medical discoveries are made by observing associations and then designing experiments to test these hypotheses. However, observing and quantifying associations in images can be difficult because of the wide variety of features, patterns ...
R. Poplin +7 more
semanticscholar +1 more source
NSAIDs and cardiovascular risk
Journal of Cardiovascular Medicine, 2017NSAIDs are the most largely used class of drugs in the world, due to their large use in many diseases, in particular for the systemic inflammatory diseases. Nevertheless, today NSAIDs are less used for some of these diseases, due to several side-effects correlated to these drugs. The antiinflammatory mechanism of NSAIDs consist in the inibhition of two
Marsico F, Paolillo S, Filardi PP
openaire +3 more sources
Perioperative Cardiovascular Risk Assessment and Management for Noncardiac Surgery: A Review.
Journal of the American Medical Association (JAMA), 2020Importance Perioperative cardiovascular complications occur in 3% of hospitalizations for noncardiac surgery in the US. This review summarizes evidence regarding cardiovascular risk assessment prior to noncardiac surgery.
N. Smilowitz, J. Berger
semanticscholar +1 more source
The Consultant Pharmacist, 2006
A case on cardiovascular risk reduction is presented. Multiple cardiovascular risks (dyslipidemia, hypertension, and diabetes) are addressed. Management of the metabolic syndrome and appropriate testing for the newer cardiovascular marker, C-reactive protein, are also discussed.
openaire +2 more sources
A case on cardiovascular risk reduction is presented. Multiple cardiovascular risks (dyslipidemia, hypertension, and diabetes) are addressed. Management of the metabolic syndrome and appropriate testing for the newer cardiovascular marker, C-reactive protein, are also discussed.
openaire +2 more sources
Cardiovascular risk in vasculitis
Best Practice & Research Clinical Rheumatology, 2023The present review summarizes the burden, risk factors, biomarkers of and therapeutic consideration for cardiovascular disease in systemic vasculitis. Ischemic heart disease (IHD) and stroke are intrinsic features of Kawasaki disease, Takayasu arteritis, Giant Cell Arteritis (GCA), and Behcet's disease.
Durga Prasanna Misra +3 more
openaire +2 more sources
Rosiglitazone and cardiovascular risk
Current Atherosclerosis Reports, 2008A meta-analysis of 42 clinical trials suggested that rosiglitazone, a widely used thiazolidinedione, was associated with a 43% greater risk of myocardial infarction (P = 0.03) and a 64% greater risk of cardiovascular death (P = 0.06). However, a number of criticisms have been raised that potentially undermine the conclusions of this analysis.
Sanjay, Kaul, George A, Diamond
openaire +3 more sources
Obesity and cardiovascular risk
Growth Hormone & IGF Research, 2003In most industrialized countries, 40-60% of the population is now overweight or obese. Obesity has recently been recognized as a major modifiable risk factor for cardiovascular disease, second only to cigarette smoking. Excess weight and obesity markedly increase the risk for hypertension, diabetes, coronary artery disease and congestive heart failure ...
openaire +2 more sources
Hyperglycaemia and cardiovascular risk
Acta Diabetologica, 2003Cardiovascular diseases represent, today, the principal cause of mortality in the general population, especially in subjects with type 2 diabetes mellitus. In these patients the risk of death from cardiovascular diseases is equal to that of non-diabetic subjects with a previous episode of myocardial infarction.
Palumbo F +3 more
openaire +3 more sources
Annales d'Endocrinologie, 2021
FGF23 is a protein secreted in the plasma by bone cells. In the kidney, FGF23 can activate an FGF receptor in the presence of its co-receptor αKlotho. FGF23 controls the renal phosphate reabsorption and calcitriol metabolism. When renal function declines, plasma FGF23 concentration raises and FGF23 can stimulate FGFRs in the absence of αKlotho.
openaire +2 more sources
FGF23 is a protein secreted in the plasma by bone cells. In the kidney, FGF23 can activate an FGF receptor in the presence of its co-receptor αKlotho. FGF23 controls the renal phosphate reabsorption and calcitriol metabolism. When renal function declines, plasma FGF23 concentration raises and FGF23 can stimulate FGFRs in the absence of αKlotho.
openaire +2 more sources